Table 4.
Effect of Topo I Inhibitors on Experimental Liver Metastases of Murine CT-26 Colon Carcinoma When Injected Intravenously.
| Treatment | Liver Metastasis | ||
| Incidence | Liver Weight (g) | Median, n (range) | |
| Control | 9/9 | 5.26 ± 0.54 | 55 (45–80) |
| Control* | 5/5 | 1.56 ± 0.49 | 9 (5–12) |
| Lipo-DB67 | 10/10 | 1.85 ± 0.65†,‡ | 7 (0–14)§,¶ |
| Irinotecan | 10/10 | 3.51 ± 1.27† | 34 (10–55)§ |
Balb/C mice were injected in the spleen with 5 x 104 viable CT-26 cells on day 0. Seven days later, mice were splenectomized. On day 14 after cell injection, groups of mice were treated on a schedule of daily injection for 5 days (qdx5/1) with i.v. injections of 7 mg/kg liposomal DB67 or 55 mg/kg irinotecan. Mice were sacrificed on day 21.
Median is the value of the variable that has an equal number of items on either side and divides a frequency distribution into two halves.
On day 14 after cell injection.
P < .005 as compared to control (no treatment).
P < .01 as compared to irinotecan.
P < .001 as compared to control.
P < .001 as compared to irinotecan.